Cited by 161Cancer-related Molecular PathwaysHeat shock proteins researchUbiquitin and proteasome pathways

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Inactivation of the p53-homologue p73 by the mdm2-oncoprotein

Dobbelstein, Matthias, Wienzek, Sandra, König, Claudia, Roth, Judith·1999·Oncogene

DOI 10.1038/sj.onc.1202512

Open this paper in CoChat — free account

Abstract

The p73beta protein shares structural and functional similarities with the tumor suppressor gene product p53. Both proteins activate transcription from p53-responsive promoters. p53's activity is antagonized by the mdm2 protein (also termed hdm2 in human cells). Complex formation between p53 and mdm2 results in p53's transcriptional inactivation and destabilization. Here we show that overexpression of mdm2 reduces p73beta's ability to activate transcription, too. The mdm2 protein forms a specific complex with p73beta in vitro with an efficiency comparable to p53-binding. Further, both p73beta and p53 relocalize a transport-defective mutant of mdm2 from the cytoplasm to the nucleus, arguing that complex formation occurs in vivo as well. Mutational analysis suggests that the interaction between p73beta and mdm2 follows structural principles analogous to the p53-mdm2-complex. Whereas p53 is destabilized in the presence of mdm2, the amount of intracellular p73beta was not detectably reduced by mdm2. The carboxyterminal RING finger domain of mdm2 was found to be required to reduce the intracellular abundance of p53, but it was dispensable for transcriptionally inactivating either p53 or p73beta. Our results suggest that the autoregulatory feedback loop between p53 and mdm2 also controls p73's activity, but that mdm2-mediated protein degradation is unique to p53.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1202512

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
p53, guardian of the genome
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“…(Figure 3e), further supporting the concept that the p73b interacts with mdm2 in vivo as well as in vitro. mdm2 does not detectably destabilize p73 In the presence of mdm2, p53 is rapidly degraded, leading to a reduced steady-state level of the protein (Haupt et al., 1997; Kubbutat et al., 1997).”
Background
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers
Kaghad, M., Bonnet, H., Yang, A., Créancier, L., Biscan, J.-C., Valent, A., Minty, A. J., Chalon, P., Lélias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,659

Flagged first, then by citations

Show all 40 references

Research works printed but not linked: 2

Chen J, Marechal V and Levine AJ. . 1993 Mol. Cell. Biol. 13: 4107–4114. · DOI
Dobblestein M and Roth J. . 1997 J. Gen. Virol. in press.

Sorted by citations

Items 101–160 of 160

Spatiotemporal Switch from ΔNp73 to TAp73 Isoforms during Nephrogenesis
Saifudeen, Z. R., Diavolitsis, V. M., Stefkova, J., Dipp, S., Fan, H., & El-Dahr, S. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414575200 · Cited by 29
Analysis of Molecular Interactions of the p53-Family p51(p63) Gene Products in a Yeast Two-Hybrid System: Homotypic and Heterotypic Interactions and Association with p53-Regulatory Factors
Kojima, T., Ikawa, Y., & Katoh, I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4486 · Cited by 29
MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population
Akkız, H., Sümbül, A. T., Bayram, S., Bekar, A., & Akgöllü, E. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.04.008 · Cited by 28
Negative regulation of p53 by Ras superfamily protein RBEL1A
Lui, K., An, J., Montalbano, J., Shi, J., Corcoran, C. A., He, Q., Sun, H., Sheikh, M. S., & Huang, Y. (2013) · Journal of Cell Science · doi:10.1242/jcs.118117 · Cited by 27
Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells
VanderBorght, A., Valckx, A., Dun, J. V., Grand‐Perret, T., Schepper, S. D., Vialard, J., Janicot, M., & Arts, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209667 · Cited by 27
Design of a novel MDM2 binding peptide based on the p53 family
Madhumalar, A., Jun, L. H., Brown, C. J., Lane, D. P., & Verma, C. S. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9516 · Cited by 26
Matrine-induced apoptosis in Hep3B cells via the inhibition of MDM2
Zhou, N., Li, J., Li, T., Chen, G., Zhang, Z., & Si, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5999 · Cited by 26
Retracted
p73: Structure and function
Ichimiya, S., Nakagawara, A., Sakuma, Y., Kimura, S., Ikeda, T., Satoh, M., Takahashi, N., Sato, N., & Mori, M. (2000) · Pathology International · doi:10.1046/j.1440-1827.2000.01090.x · Cited by 26
The Expression of P73, P21 and MDM2 Proteins in Gliomas
Kamiya, M., & Nakazato, Y. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1019633910603 · Cited by 23
MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells
Kubo, N., Okoshi, R., Nakashima, K., Shimozato, O., Nakagawara, A., & Ozaki, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.043 · Cited by 22
TNF-α-mediated apoptosis in vascular smooth muscle cells requires p73
Tang, V., Dhirapong, A., Yabes, A., & Weiss, R. H. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00477.2004 · Cited by 22
p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies
Horvat, A., Tadijan, A., Vlašić, I., & Slade, N. (2021) · Cancers · doi:10.3390/cancers13122885 · Cited by 22
p73-Binding Partners and Their Functional Significance
Ozaki, T., Kubo, N., & Nakagawara, A. (2010) · International Journal of Proteomics · doi:10.1155/2010/283863 · Cited by 20
Identification of functional DNA variants in the constitutive promoter region of MDM2
Lalonde, M., Ouimet, M., Larivière, M., Kritikou, E. A., & Sinnett, D. (2012) · Human Genomics · doi:10.1186/1479-7364-6-15 · Cited by 19
Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2
Ozaki, T., Nakamura, M., & Shimozato, O. (2015) · Biomolecules · doi:10.3390/biom5042854 · Cited by 18
Induction of p73β by a naphthoquinone analog is mediated by E2F‐1 and triggers apoptosis in HeLa cells
Kang, K.-H., Lee, J.-H., Kim, K., Ham, S., Kim, M.-Y., & Choi, K. H. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02921-6 · Cited by 18
NBP is the p53 homolog p63
Zeng, X., Zhu, Y., & Lu, H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.2.215 · Cited by 19
Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy
Du, W., Yi, Y., Zhang, H., Bergholz, J. S., Wu, J., Ying, H., Zhang, Y., & Xiao, Z. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063179 · Cited by 18
Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System
Lavelin, I., Beer, A., Kam, Z., Rotter, V., Oren, M., Navon, A., & Geiger, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008503 · Cited by 17
The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing
Zawacka‐Pankau, J. (2020) · Cancers · doi:10.3390/cancers12092717 · Cited by 16
Downregulation of AKT and MDM2, Melatonin Induces Apoptosis in AGS and MGC803 Cells
Song, J. H., Ma, S., Luo, J., Liu, H., Li, L., Zhang, Z., Chen, L., & Zhou, R. (2019) · The Anatomical Record · doi:10.1002/ar.24101 · Cited by 17
A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation
Gu, J., Rubin, R. M., & Yuan, Z.-M. (2001) · Oncogene · doi:10.1038/sj.onc.1204454 · Cited by 17
Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73β function through protein-protein interactions
Kim, K., Kim, T.-S., Kang, K., & Choi, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204839 · Cited by 15
Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors
Omran, Z., Dalhat, M. H., Abdullah, O., Kaleem, M., Hosawi, S. B. I., Al-Abbasi, F. A., Wu, W., Choudhry, H., & Alhosin, M. (2021) · Cancers · doi:10.3390/cancers13081916 · Cited by 15
The C-terminal SAM domain of p73 binds to the N terminus of MDM2
Neira, J. L., Díaz-García, C., PRIETO, M. J. E., & Coutinho, A. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.01.019 · Cited by 13
Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status
Domínguez, G., Silva, J., Silva, J. M., García, J. M. P., Larrondo, F. J., Vargas, J., Sanfrutos, L., Provencio, M., España, P., & Bonilla, F. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1123 · Cited by 12
Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment
Almeida, J., Mota, I. N. R., Skoda, J., Sousa, E., Cidade, H. M., & Saraiva, L. (2022) · Cancers · doi:10.3390/cancers14246212 · Cited by 11
Pathway Crosstalk Analysis of Microarray Gene Expression Profile in Human Hepatocellular Carcinoma
Zhou, X., Zheng, R., Zhang, H., & He, T. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9855-x · Cited by 11
p73 transcriptional activity increases upon cooperation between its spliced forms
Alarcon-Vargas, D., Fuchs, S. Y., Deb, S., & Ronai, Z. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203311 · Cited by 11
Correction: Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy
Du, W. D., Yi, Y., Zhang, H., Bergholz, J. S., Wu, J., Ying, H., Zhang, Y., & Xiao, Z. J. (2013) · PLoS ONE · doi:10.1371/annotation/f1a4d192-57b9-43fb-a248-379e0f5a46ca · Cited by 11
Increased mdm-2 Expression in a p53-Independent Manner Blocks UV-Induced Cell Cycle Arrest and Apoptosis in Human Osteosarcoma Cells
Dong, Y., Yang, H. L., Elliott, M. J., & McMasters, K. M. (2003) · Tumor Biology · doi:10.1159/000073842 · Cited by 8
Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA
Lunec, J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1267 · Cited by 8
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
On, J. L., Ghaderi, S., Rittmann, C., Hoffmann, G., Gier, F., Woloschin, V., Tu, J., Bhatia, S., Kulik, A., Niederacher, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031078 · Cited by 7
p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis
Tashakori, M., Zhang, Y., Xiong, S., You, M. J., & Lozano, G. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0346 · Cited by 6
Therapeutic considerations for Mdm2: not just a one trick pony
Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 6
MDM2: RING Finger Protein and Regulator of p53
Wu, L., & Maki, C. G. (2005) · Springer eBooks · doi:10.1007/0-387-27421-9_34 · Cited by 4
Delineating functional mechanisms of the p53/p63/p73 family of transcription factors through identification of protein–protein interactions using interface mimicry
Guven‐Maiorov, E., Sakakibara, N., Ponnamperuma, R. M., Dong, K., Matar, H., King, K. E., & Weinberg, W. C. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23405 · Cited by 3
Effects of ΔNp73β on cisplatin treatment in colon cancer cells
Lööf, J., Pfeifer, D., Ding, Z., Sun, X., & Zhang, H. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20835 · Cited by 2
Impact of MDM2 SNP309T>G Polymorphism: Increased Risk of Developing Non Small Cell Lung Cancer and Poor Prognosis in Indian Patients
Javid, J. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000165 · Cited by 2
MDM2 binds and suppresses RNA polymerase III to restrain the innate immune response to cytosolic DNA
Weber, S., Manzini, V., Dietrich, H., Schotte, H., Moshkovskii, S. A., Hackert, P., Duman, E. T., Vu, N. Q., Prokakis, E., Salinas, G., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01834-2 · Cited by 1
TP63, TP73: The Guardian’s Elder Brothers
Courtois-Cox, S., Hainaut, P. L., & de Fromentel, C. C. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_3 · Cited by 1
Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide.
Schlott, T., Taubert, H. W., Fayyazi, A., Schweyer, S., Bartel, F., Korabiowska, M., & Brinck, U. (2004) · PubMed · Cited by 1
A FRET‐Based Fluorescent Probe to Screen Anticancer Drugs, Inhibiting p73 Binding to MDM2
Han, A. R., Durgannavar, T., Ahn, D., & Chung, S. J. (2020) · ChemBioChem · doi:10.1002/cbic.202000660 · Cited by 1
Mdm2 and ARF
Klotzbücher, A., & Kubbutat, M. H. G. (2002) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-59259-153-4_10 · Cited by 1
On the structure-function relationship of p73
Nyman, U. (2009) · Figshare
p73 Affects Cell Fate and Tumorigenesis
Ramadan, S. M., Sayan, E., Oberst, A., Chikh, A., Pietroni, V., Rufini, A., Melino, G., & Bernassola, F. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch20
The Role of p53 and p73 Genes in Tumor Formation
(2005) · Handbook of immunohistochemistry and in situ hybridization of human carcinomas · doi:10.1016/s1874-5784(05)80016-9
DISSECTING THE P53 PATHWAY BY MEANS OF SMALL MOLECULE- MEDIATED REACTIVATION AND COMPUTATIONAL BIOLOGY
Enge, M. (2009) · Figshare
Mutational analysis of MDM2 gene in hepatocellular carcinoma
Ali, H. M., Bhatti, S., Iqbal, M. N., Ali, S. M., Ahmad, A., Irfan, M. I., Ali, S., & Mutational, M. A. (2015)
Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin
Tonsing-Carter, E. Y. (2014) · ProQuest Demo Repository · doi:10.7912/c2/308
IN VIVO SIGNIFICANCE OF THE MDM4 AND P73 INTERACTION DURING DEVELOPMENT AND TUMORIGENESIS
Tashakori, M. (2015) · Digital Commons-TMC (Texas Medical Center)
A regulatory network of Mdm2 and members of the Polycomb Group (PcG) family
Wienken, M. M. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5475
Expression of MDM2 protein and mRNA in condyloma acuminata
Zhu, L., Tu, Y., Changzheng, H., Houjun, L., & Feng, A. (2004) · Current Medical Science · doi:10.1007/bf02831118
Identification of novel and direct target genes of p73
Lapi, E. (2008) · Cineca Institutional Research Information System (Tor Vergata University)
MDM2 promoter polymorphism (rs2279744) and serum estrogen level are associated with increased risk of epithelial ovarian cancer: A case-control study
Dholariya, S. J., Takodara, S., Mir, R., & Saxena, A. (2018) · International Journal of Clinical Biochemistry and Research · doi:10.18231/2394-6377.2018.0112
MDM2 as a chromatin modifier
Gerber, S. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8184
The MDM2 oncoprotein antagonizes Poly(ADP-ribosyl)ation
Giansanti, C. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9741
Development of a Bipyrimidineamide based α-Helix Mimetic Lead Compound for efficient Targeting of MDM2 in Triple-Negative Breast CancerPreprint
On, J. L., Woloschin, V., Gier, F., Tu, J., Bhatia, S., Lenz, T., Kulik, A., Stühler, K., Niederacher, D., Neubauer, H. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.02.582899
Improving neuroblastoma therapy with a new p53 family-activating agent
Almeida, J., Resende, D. I. S. P., da Silva, R. D. F., Villasante, A., Murphy, C., Zingales, V., Palmeira, A., Škoda, J., Broso, F., Vadivellu, A., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178295
Coopération entre les isoformes TAp73 et la signalisation TGF-β dans la régulation de l'expression de la NO Synthase inductible
Cabrié, A. (2017) · theses.fr (ABES) · doi:10.70675/df567380z9a01z4262z9a43z7666c8df7b0f

Authors: Dobbelstein, M., Wienzek, S., König, C., & Roth, J.
Affiliations: Philipps University of Marburg (DE)
ORCID: Dobbelstein, Matthias
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 1999-03-25
Volume: 18
Issue: 12
Pages: 2101-2106
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1202512
OpenAlex: W2312957642
Cited by: 161
References: 40
Citations by year: 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 6 · 2014: 6 · 2013: 4 · 2012: 5
FWCI: 7.98
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: p53, MDM2, transcriptional inactivation, protein-protein interaction, RING domain, protein degradation, autoregulatory loop, tumor suppressor proteins, nuclear translocation
MeSH terms: Tumor Protein p73, Biological Transport, Cell Compartmentation, Cell Nucleus, Cytoplasm, DNA-Binding Proteins, Nuclear Proteins, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcriptional Activation, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inactivation of the p53-homologue p73 by the mdm2-oncoprotein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks